Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.
IPO allocation of 2,333,333 shares at $15.00 ($35.0M from underwriters, ~July 24 IPO) plus post-IPO open-market: 50,000 shares at $22.31 and 7,905 shares at $18.25. Current price $18.06 (+20.4% vs IPO price; -17.7% vs avg open-market buy of ~$21.93). Gene-editing / CRISPR biotech; Aghazadeh sits on board.
Bought 170,500 shares at $11.509 avg on July 27. Current $11.58 (+0.6% since buy). Post-buy direct holding 308,946 shares. Also transferred 92,721 shares to a Family Trust on same date (not a sale).
Bought 20,000 shares at $22.73–$22.86 (avg $22.77) on July 28. Current $22.80 (+0.1% since buy). Post-buy direct holding 85,780 shares. California state commercial bank (Ontario, CA). Steady director accumulator.
AIThe day in insider buying
SEC Form 4 Insider Scan — July 29, 2026
Scanned the last 24 hours of EDGAR Form 4 filings (filed July 28–29, 2026). 3 qualifying buys (≥ $250K, transaction type P) totalling $38.7M across 3 issuers. The total is dominated by a single biotech IPO commitment; stripping that out leaves ~$2.4M in secondary-market buys.
Headline filings
SCTX — Behzad Aghazadeh / Avoro Capital Advisors LLC (Director, 10% Owner) acquired 2,391,238 shares ≈ $36.3M total: IPO allocation of 2,333,333 shares at $15.00 from underwriters (~July 24 IPO) plus open-market follow-on of 57,905 shares at avg ~$21.93. Now at $18.06 (+20.4% vs IPO price; -17.7% vs open-market avg). Gene-editing / CRISPR biotech. (filing)
ACI — Thomas M. Moriarty (EVP, M&A and Corporate Affairs) bought 170,500 shares ≈ $1.96M at $11.51 avg on July 27. Current $11.58 (+0.6% since buy). (filing)
CVBF — Raymond V. O'Brien III (Director) bought 20,000 shares ≈ $455K at $22.77 avg on July 28 (range $22.73–$22.86). Current $22.80 (+0.1% since buy). Now holds 85,780 shares directly. (filing)
SCTX headline: Avoro's board-member Aghazadeh committed ~$35M at the Scribe Therapeutics IPO and then chased additional shares in the open market above the offer price — a textbook conviction buy at IPO by a lead institutional backer who also sits on the board. The stock has since pulled back from its $22+ post-IPO highs to $18.06, meaning the open-market tranche is underwater while the IPO tranche is still +20%. Worth watching for further accumulation.
ACI conviction buy: Senior M&A executive spending ~$2M at market on Albertsons signals near-term confidence. At $11.51 vs. $11.58 current, Moriarty is essentially flat since the buy. Also transferred 92,721 shares to a Family Trust on the same date — not a sale but a housekeeping move. No competing bids or public events flagged.
CVBF quiet accumulator: Raymond O'Brien has been a steady director buyer at CVB Financial. $455K in a single session on July 28, paying $22.73–$22.86, with the stock now at $22.80. Regional bank in Ontario, CA; quiet but consistent insider accumulation pattern.
No cluster buying (multiple insiders same issuer same day) was detected among qualifying transactions today.
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's
stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what
average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free,
and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.